BioCryst Pharmaceuticals, Idera Pharmaceuticals to merge
MLex Summary: BioCryst Pharmaceuticals said on Monday it will merge with Idera Pharmaceuticals in a deal that would give BioCryst shareholders 51.6 percent of the unnamed company and Idera shareholders 48.4...To view the full article, register now.
Already a subscriber? Click here to view full article